Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALM 223

Next Previous
Drug Profile

ALM 223

Alternative Names: ALM-223; IL-2muFc - Almirall S.A; SIM 0278

Latest Information Update: 28 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Developer Almirall S.A.; Simcere Pharmaceutical Group
  • Class Anti-inflammatories; Antidementias; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Skin disorder therapies; Urologics
  • Mechanism of Action Interleukin 2 replacements; Natural killer cell stimulants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Atopic dermatitis; Lupus nephritis
  • Phase I Autoimmune disorders
  • No development reported Alzheimer's disease

Most Recent Events

  • 28 Sep 2026 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in China (SC, Injection)
  • 15 Jul 2026 Phase-II clinical trials in Lupus nephritis in China (Parenteral, Injection), prior to July 2026 (Simcere Pharmaceutical Group pipeline, July 2026) (NCT07393451)
  • 06 Jun 2026 Pharmacodynamics, adverse events and pharmacokinetics data from a phase I trial in Autoimmune disorders presented at the 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top